TY - JOUR
T1 - Persistent idiopathic hyperphosphatasemia from bone alkaline phosphatase in a healthy boy
AU - Whyte, Michael P.
AU - Ma, Nina S.
AU - Mumm, Steven
AU - Gottesman, Gary S.
AU - McAlister, William H.
AU - Nenninger, Angela R.
AU - Bijanki, Vinieth N.
AU - Ericson, Karen L.
AU - Magnusson, Per
N1 - Funding Information:
Funded in part by: Shriners Hospitals for Children , USA, The Clark and Mildred Cox Inherited Metabolic Bone Disease Research Fund and The Hypophosphatasia Research Fund at The Barnes-Jewish Hospital Foundation , USA and ALF grants from Region Östergötland, Sweden .
Funding Information:
Our study reflects the skill and dedication of the nursing and laboratory staffs at the Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children - St. Louis, St. Louis, MO, USA. Ms. Margaret Huskey and Ms. Shenghui Duan performed the mutation analyses at the Washington University School of Medicine, St. Louis, MO, USA. Diana Atanasova, MSc, and Cecilia Halling Linder, PhD, Linköping University, Sweden, assisted in the ALP characterizations. Ms. Sharon McKenzie provided expert secretarial help. Nina S. Ma, MD was supported by the Ed and Jeannette Kerr Family Endowed Chair in Endocrinology at Children’s Hospital Colorado, Aurora, CO, USA.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/9
Y1 - 2020/9
N2 - Alkaline phosphatase (ALP) in humans comprises a family of four cell-surface phosphomonoester phosphohydrolase isozymes. Three genes separately encode the “tissue-specific” ALPs whereas the fourth gene encodes ubiquitous homodimeric “tissue-nonspecific” ALP (TNSALP) richly expressed in bone, liver, kidney, and developing teeth. TNSALP monomers have five putative N-linked glycosylation sites where different post-translational modifications account for this isozyme's distinctive physicochemical properties in different organs. Three bone-derived TNSALP (BALP) isoforms (B/I, B1, and B2) are present in healthy serum, whereas a fourth BALP isoform (B1x) can circulate in chronic kidney disease. Herein, we report a healthy boy with persistent hyperphosphatasemia due to BALP levels two- to threefold higher than age-appropriate reference values. High-performance liquid chromatography, electrophoresis, heat inactivation, catalysis inhibition, and polyethylene glycol precipitation revealed increased serum B/I, B1, and B2 differing from patterns found in skeletal diseases. B/I was ~23-fold elevated. Absence of mental retardation and physical stigmata excluded Mabry syndrome, the ALP-anchoring disorder causing hyperphosphatasemia. Routine biochemical studies indicated intact mineral homeostasis. Serum N-terminal propeptide of type I procollagen (P1NP) level was normal, but C-terminal cross-linking telopeptide of type I collagen (CTX) level was elevated. However, radiological studies showed no evidence for a generalized skeletal disturbance. Circulating pyridoxal 5′-phosphate, a TNSALP natural substrate, was not low despite the laboratory hyperphosphatasemia, thereby suggesting BALP phosphohydrolase activity was not elevated endogenously. Mutation analysis of the ALPL gene encoding TNSALP revealed no defect. His non-consanguineous healthy parents had serum total ALP activity and BALP protein levels that were normal. Our patient's sporadic idiopathic hyperphosphatasemia could reflect altered post-translational modification together with increased expression and/or impaired degradation of BALP.
AB - Alkaline phosphatase (ALP) in humans comprises a family of four cell-surface phosphomonoester phosphohydrolase isozymes. Three genes separately encode the “tissue-specific” ALPs whereas the fourth gene encodes ubiquitous homodimeric “tissue-nonspecific” ALP (TNSALP) richly expressed in bone, liver, kidney, and developing teeth. TNSALP monomers have five putative N-linked glycosylation sites where different post-translational modifications account for this isozyme's distinctive physicochemical properties in different organs. Three bone-derived TNSALP (BALP) isoforms (B/I, B1, and B2) are present in healthy serum, whereas a fourth BALP isoform (B1x) can circulate in chronic kidney disease. Herein, we report a healthy boy with persistent hyperphosphatasemia due to BALP levels two- to threefold higher than age-appropriate reference values. High-performance liquid chromatography, electrophoresis, heat inactivation, catalysis inhibition, and polyethylene glycol precipitation revealed increased serum B/I, B1, and B2 differing from patterns found in skeletal diseases. B/I was ~23-fold elevated. Absence of mental retardation and physical stigmata excluded Mabry syndrome, the ALP-anchoring disorder causing hyperphosphatasemia. Routine biochemical studies indicated intact mineral homeostasis. Serum N-terminal propeptide of type I procollagen (P1NP) level was normal, but C-terminal cross-linking telopeptide of type I collagen (CTX) level was elevated. However, radiological studies showed no evidence for a generalized skeletal disturbance. Circulating pyridoxal 5′-phosphate, a TNSALP natural substrate, was not low despite the laboratory hyperphosphatasemia, thereby suggesting BALP phosphohydrolase activity was not elevated endogenously. Mutation analysis of the ALPL gene encoding TNSALP revealed no defect. His non-consanguineous healthy parents had serum total ALP activity and BALP protein levels that were normal. Our patient's sporadic idiopathic hyperphosphatasemia could reflect altered post-translational modification together with increased expression and/or impaired degradation of BALP.
KW - ALPL gene
KW - Bone
KW - Enzymopathy
KW - Hypophosphatasia
KW - Isoenzyme
KW - Isoform
KW - Isozyme
KW - Mabry syndrome
KW - Osteoblast
KW - Phosphohydrolase
KW - Pyridoxal 5′-phosphate
KW - Skeleton
KW - Vitamin B
UR - http://www.scopus.com/inward/record.url?scp=85087213324&partnerID=8YFLogxK
U2 - 10.1016/j.bone.2020.115459
DO - 10.1016/j.bone.2020.115459
M3 - Article
C2 - 32474245
AN - SCOPUS:85087213324
SN - 8756-3282
VL - 138
JO - Bone
JF - Bone
M1 - 115459
ER -